Stemline Therapeutics

Stemline Therapeutics pertence à Menarini Group. Menarini Group tem presença direta em 4 países.

Menarini Group possui 3 subsidiárias incluindo Berlin Chemie, Menarini APAC e Stemline Therapeutics.

Eles estão dentro:

• Farmacêutica75%
• Biotecnologia25%

Veja o organograma con seus 8 executivos principais

Biografias mais buscadas da Stemline Therapeutics

• Ivan Bergstein, Director, Chief Executive Officer and President
• David Gionco, Senior Vice President of Finance and Chief Accountin...
• Ken Hoberman, Chief Operating Officer

Criar um alerta
para seguir os movimentos de executivos da Stemline Therapeutics.

Menarini Group possui 2.282 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
• Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
• Histogen has filed for bankruptcy protection  (publicado em 19 de abril de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Vik Bajaj - Director da Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board da Sensorion

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de Stemline Therapeutics

• RSS News Feeds | Stemline Therapeutics
• Menarini Group Completes Acquisition of Stemline Therapeutics | Stemline Therapeutics
• Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million | Stemline Therapeutics
• Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020 | Stemline Therapeutics
• Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results | Stemline Therapeutics
• Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference | Stemline Therapeutics
• Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers | Stemline Therapeutics
• Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference | Stemline Therapeutics
• Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting | Stemline Therapeutics
• Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer | Stemline Therapeutics
• View more press releases Close

Redes sociais sobre Stemline Therapeutics

• Stemline Therapeutics na Wikipedia, Google News e Yahoo Finance
• Stemline Therapeutics na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Ivan Bergstein

Ligue para a Stemline Therapeutics em +1 646...

Veja o organograma

Register to receive your alert

Relatório um erro